Classification of diabetes. World Health Organization 2019. What’s new?
https://doi.org/10.14341/DM12405
Abstract
The review focuses on the new WHO classification published in 2019. Unlike the previous classification, this classification does not recognize subtypes of T1DM and T2DM and offers new types of diabetes: “hybrid types of diabetes” and “unclassified diabetes”. This classification provides practical guidance to clinicians for assigning a type of diabetes to individuals and choose appropriate treatment (whether or not to start treatment with insulin), particularly at the time of diagnosis. This review presents the variety of forms of diabetes, the features of their clinical picture, and also emphasizes the importance of molecular genetic and immunological studies to identify types of diabetes and determine personalized therapy. The selection of “hybrid forms” of diabetes is due to the fact that the treatment of these types of diabetes has its own characteristics associated with the specific pathogenesis of diseases. However, it is obvious that further studies should relate to the study of the mechanisms of damage and decrease in the function of в-cells. Perhaps future classification systems and, as a consequence, personalized treatment will focus on various mechanisms of damage to β-cells.
About the Authors
Irina V. Kononenko
Endocrinology Research Centre
Russian Federation
Competing Interests: not
Russian Federation
MD, PhD, leading research associate, eLibrary SPIN 6528-7986.
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests: not
Olga M. Smirnova
Endocrinology Research Centre
Russian Federation
Competing Interests: not
Russian Federation
MD, PhD, Professor, chief research associate, eLibrary SPIN: 9742-8875
Moscow
Competing Interests: not
Aleksandr Y. Mayorov
Endocrinology Research Centre
Russian Federation
Competing Interests: not
Russian Federation
MD, PhD, eLibrary SPIN: 4275-7779.
Moscow
Competing Interests: not
Marina V. Shestakova
Endocrinology Research Centre; I.M. Sechenov First Moscow State Medical University
Russian Federation
Competing Interests: not
Russian Federation
MD, PhD, Professor, eLibrary SPIN: 7584-7015.
Moscow
Competing Interests: not
References
1. Diabetes mellitus. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1965;310:1-44.
2. WHO/NCD/NCS/99.2. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. World Health OrganizationDepartment of Noncommunicable Disease SurveillanceGeneva; 1999. 65 р.
3. Classification of diabetes mellitus. World Health Organization, 2019. Available from: https://apps.who.int/iris/handle/10665/325182
4. Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018;6(2):122-129. doi: https://doi.org/10.1016/S2213-8587(17)30362-5
5. Cleland SJ, Fisher BM, Colhoun HM, et al. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462-1470. doi: https://doi.org/10.1007/s00125-013-2904-2
6. Dedov II. Sakharnyy diabet: mnogoobraziye klinicheskikh form. Ed by I.I. Dedov, M.V. Shestakova. Moscow: Meditsinskoye informatsionnoye agentstvo; 2016. 218 p. (In Russ).
7. Shields BM, Peters JL, Cooper C, et al. Can clinical features be used to differentiate type 1from type 2 diabetes? A systematic review ofthe literature. BMJ Open. 2015;5(11):e009088. doi: https://doi.org/10.1136/bmjopen-2015-009088.
8. Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what has changed over the decade? Therapeutic archive. 2019;91(10):4-13. (In Russ). doi: https://doi.org/10.26442/00403660.2019.10.000364
9. Dedov II, Shestakova MV, Vikulova OK, et al. Atlas of diabetes register in Russian Federation, status 2018. Diabetes mellitus. 2019;22(S2-2):4-61. (In Russ). doi: https://doi.org/10.14341/DM12208
10. Dedov II. Sakharnyy diabet tipa 1: realii i perspektivy. Ed by I.I. Dedov, M.V. Shestakova. Moscow: Meditsinskoye informatsionnoye agentstvo; 2016. 502 р. (In Russ).
11. Mayer-Davis EJ, Kahkoska AR, Jefferies C, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatric Diabetes. 2018;19(Suppl. 27):7-19. doi: https://doi.org/10.1111/pedi.12773
12. Patterson CC, Dahlquist GG, Gyurus E, et al. EURODIAB study group incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-2020: a multicentre prospective registration study. Lancet. 2009;373(9680):2027-2033. doi: https://doi.org/10.1016/S0140-6736(09)60568-7
13. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Centers for Disease Control and Prevention; 2014. Available from: https://templatelab.com/files/national-diabetes-report-2014.pdf
14. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36-45. doi: https://doi.org/10.1038/ncpendmet0351
15. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y; Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342(5):301-307. doi: https://doi.org/10.1056/NEJM200002033420501
16. Imagawa A, Hanafusa T, Awata T, et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acuteonset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus. J Diabetes Investig. 2012;3(6):536-539. doi: https://doi.org/10.1111/jdi.12024
17. Cho YM, Kim JT, Ko KS, et al. Fulminant type 1 diabetes in Korea: high prevalence among patients with adult onset type 1 diabetes. Diabetologia. 2007;50(11):2276-227. doi: 10.1007/s00125-007-0812-z
18. Luo S, Zhang Z, Li X, et al. Fulminant type 1 diabetes: a collaborative clinical cases investigation in China. Acta Diabetol. 2013;50(1):53-59. doi: https://doi.org/10.1007/s00592-011-0362-1
19. Zhu B, Wu J. Fulminant Type 1 diabetes mellitus caused by drug reaction with eosinophilia and systemic symptoms (DRESS): a case report and review of the literature. Front Endocrinol (Lausanne). 2019;10:474. doi: https://doi.org/10.3389/fendo.2019.00474
20. Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab. 2007;3(1):36-45. doi: https://doi.org/10.1038/ncpendmet0351
21. IDF Diabetes Atlas. 9th Edition. Brussels: International Diabetes Federation; 2019. Available from: https://diabetesatlas.org/en/
22. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64-91. doi: https://doi.org/10.1111/nyas.12098
23. Narayan KM. Type 2 diabetes: why we are winning the battle but losing the war. 2015 Kelly West Award Lecture. Diabetes Care. 2016;39(5):653-663. doi: https://doi.org/10.2337/dc16-0205
24. Kanaya AM, Herrington D, Vittinghoff E, et al. Understanding the high prevalence of diabetes in U.S. south Asians compared with four racial/ethnic groups: the MASALA and MESA studies. Diabetes Care. 2014;37(6):1621-1628. doi: https://doi.org/10.2337/dc13-2656
25. Shestakova MV, Sukhareva OYu. Sakharnyy diabet 2 tipa: legko li postavit’ diagnoz i kak vybrat’ lecheniye. Doktor. Ru. 2017;(13-14):44-51. (In Russ).
26. Dedov II, et al.; FGBU «Endokrinologicheskiy nauch. tsentr» MZ RF, GBOU VPO «Pervyy MGMU im. I.M. Sechenova» MZ RF. Sakharnyy diabet tipa 2. Ot teorii kpraktike. Ed by I.I. Dedov, M.V. Shestakova. Moscow: Meditsinskoye informatsionnoye agentstvo; 2016. 571 р. (In Russ).
27. TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256. doi: https://doi.org/10.1056/NEJMoa1109333
28. Zimmet PZ, Tuomi T, Mackay IR, et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med. 1994;11(3):299-303. doi: https://doi.org/10.1111/j.1464-5491.1994.tb00275.x
29. Kononenko IV, Smirnova OM. Klinicheskiye, immunologicheskiye i geneticheskiye osobennosti medlenno progressiruyushchego autoimmunnogo diabeta. Diabetes mellitus. 2003;(2):42-48. (In Russ).
30. Nishimura A, Matsumura K, Kikuno S, et al. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461-2477. doi: https://doi.org/10.2147/DMSO.S191007
31. Reinehr T, Schober E, Wiegand S; DPV-Wiss Study Group. в-cell autoantibodies in children with type 2 diabetes mellitus: subgroup or misclassification? Arch Dis Child. 2006;91(6):473-477. doi: https://doi.org/10.1136/adc.2005.088229
32. Klingensmith GJ, Pyle L, Arslanian S, et al.; TODAY Study Group. The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Diabetes Care. 2010;33(9):1970-1975. doi: https://doi.org/10.2337/dc10-0373
33. Sorgjerd EP Skorpen F, Kvaloy K, et al. Time dynamics of autoantibodies are coupled to phenotypes and add to the heterogeneity of autoimmune diabetes in adults: the HUNT study, Norway. Diabetologia. 2012;55(5):1310-1851. doi: https://doi.org/10.1007/s00125-012-2463-y
34. Cervin C, Lyssenko V, Bakhtadze E, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes. 2008;57(5):1433-1437. doi: https://doi.org/10.2337/db07-0299
35. Awata T, Shimada A, Maruyama T, et al. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the stage of non-insulindependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8(5):1123-1134. doi: https://doi.org/10.1007/s13300-017-0299-7
36. Mauvais-Jarvis F, Sobngwi E, Porcher R, et al. Ketosis-prone type 2 diabetes in patients of Sub-Saharan African origin. Clinical pathophysiology and natural history of в-cell dysfunction and insulin resistance. Diabetes. 2004;53(3):645-653. doi: https://doi.org/10.2337/diabetes.533.645
37. Sobngwi E, Gautier JF. Adult-onset idiopathic Type I or ketosis-prone type II diabetes: evidence to revisit diabetes classification. Diabetologia. 2002;45(2):283-285. doi: https://doi.org/10.1007/s00125-001-0739-8
38. Molitvoslovova NA, Nikonova TV. Ketosis-prone type 2 diabetes mellitus (review of the literature). Diabetes mellitus. 2009;(3):65-69. (In Russ).
39. Kuraeva TL, Sechko EA, Zilberman LI, et al. Molecular genetic and clinical variants MODY2 and MODY3 in children in Russia. Problemy endokrinologii. 2015;61(5):14-25. (In Russ). doi: https://doi.org/10.14341/probl201561514-25
40. Pihoker C, Gilliam MK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: Results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013;98(10):4055-4062. doi: https://doi.org/10.1210/jc.2013-1279
41. Kononenko IV, Glibka AA, Zubkova NA, et al. MODY2 diagnostic issues in adults. Diabetes mellitus. 2019;22(4):384-391. (In Russ). doi: 10.14341/DM10063
42. Dickens LT, Naylor RN. Clinical management of women with monogenic diabetes during pregnancy. Curr Diab Rep. 2018;18(3):12. doi: https://doi.org/10.1007/s11892-018-0982-8
43. Kuraeva TL, Emelyanov AO. Clinical and genetic heterogeneity of neonatal diabetes mellitus (review of the literature). Diabetes mellitus. 2009;(3):10-15. (In Russ).
44. Maassen JA, Kadowaki T. Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetologia. 1996;39(4):375-382. doi: https://doi.org/10.1007/BF00400668
45. Challis BG, Semple RK. Genetic disorders of insulin action: far more than diabetes. Curr Obes Rep. 2013;2(4):293-300. doi: https://doi.org/10.1007/s13679-013-0075-6
46. Sorkina EL, Kalashnikova MF, Melnichenko GA, Tyulpakov AN. Familial partial lipodystrophy (dunnigan syndrome) due to lmna gene mutation: the first description of its clinical case in Russia. Therapeutic archive. 2015;87(3):83-87. (In Russ). doi: https://doi.org/10.17116/terarkh201587383-87
47. Woodmansey C, McGovern AP McCullough KA, et al. Incidence demographics, and clinical characteristics of diabetes of the exocrine pancreas (Type 3c): a retrospective cohort study. Diabetes Care. 2017;40(11):1486-1493. doi: https://doi.org/10.2337/dc17-0542
48. Hirata Y, Ishizu H. Elevated insulin-binding capacity of serum proteins 51. in a case with spontaneous hypoglycemia and mild diabetes not treated with insulin. Tohoku J Exp Med. 1972;107(3):277-286. doi: https://doi.org/10.1620/tjem.107.277
49. Rosenstein ED, Advani S, Reitz RE, Kramer N. The prevalence of insulin 52. receptor antibodies in patients with systemic lupus erythematosus and related conditions. J Clin Rheumatol. 2001;7(6):371-373. doi: https://doi.org/10.1097/00124743-200112000-00004
50. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. World Health Organization Guideline; 2013. Available from: https://www.guidelinecentral.com/summaries/diagnostic-criteria-and-classification-of-hyperglycaemia-first-detected-in-pregnancy/#section-society
51. Standards of Medical Care in Diabetes 2020. American Diabetes Association. Diabetes Care. 2020;43(1):1-224 [Internet]. Available from: https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/Standards_of_Care_2020.pdf
52. http://cr.rosminzdrav.ru [Internet] List of clinical guidelines [cited 2020 April 20]. Available from: http://cr.rosminzdrav.ru/clin_recomend.htm
53. Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the в-cell-centric classification schema. Diabetes Ca re. 2016;39(2):179-186. doi: https://doi.org/10.2337/dc15-1585
54. Skyler JS, Bakris GL, Bonifacio E, et al. Differentiation of diabetes by pathophysiology, natural history, and prognosis. Diabetes. 2017;66(2):241-255. doi: https://doi.org/10.2337/db16-0806
Review
For citations:
Kononenko I.V., Smirnova O.M., Mayorov A.Y., Shestakova M.V. Classification of diabetes. World Health Organization 2019. What’s new? Diabetes mellitus. 2020;23(4):329-339. (In Russ.) https://doi.org/10.14341/DM12405
Views:
18142
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
